Marta García Escolano, PhD, has a diverse work experience in scientific research and project management. Marta is currently the Chief Executive Officer at Prospera Biotech since July 2021, where they previously served as a Project Manager starting in January 2020. Prior to this, Marta worked at the Hospital General Universitario de Alicante - Fundació Fisabio from 2016 to 2020, first as a PHD Graduate Student from March 2016 to September 2019, and then as a Scientific Researcher from July 2019 to January 2020. In 2018, Marta also worked as a PHD Graduate Student at the Memorial Sloan Kettering Cancer Center from February to November. Additionally, they gained internship experience as the recipient of the "Gerónimo Forteza" grant at the Instituto de Neurociencias de Alicante from July 2015 to January 2016. Marta's earlier experience includes conducting their Diploma Thesis at the Albert-Ludwigs-Universität Freiburg im Breisgau from September 2013 to June 2014.
Marta García Escolano, PhD, completed their education in a chronological order as follows:
1. From 2009 to 2014, they attended Universitat Politècnica de València (UPV), where they pursued a Licenciatura en Biotecnología (Bachelor's degree in Biotechnology).
2. In 2013, Marta received an Erasmus Grant and studied at The University of Freiburg for one year.
3. Continuing their education, from 2014 to 2015, they attended Universitat d'Alacant and completed their Master of Science (MS) in Biomedicine.
4. Marta pursued further studies and between 2016 and 2019, they attended Universitat d'Alacant, where they earned their Doctor of Philosophy (PhD) degree in Experimental Sciences and Biomedicine.
5. In 2020, they enrolled in a program named "Celera Talent" at Celera, which they are expected to complete in 2023.
6. Currently, Marta is studying at Fundesem Business School, pursuing an International Master in Business Administration. Marta'sexpected completion date for this program is in 2022.
Sign up to view 2 direct reports
Get started
This person is not in any teams